Development of a bioreactor-system for pre-endothelialized cardiac patch generation with enhanced viscoelastic properties by combined collagen I compression and stromal cell culture
- Treatment of terminal heart failure still poses a significant clinical problem. Cardiac tissue engineering could offer autologous solutions for the replacement of non-functional myocardial tissue. So far, soft matrix construction and missing large scale prevascularization prevented the application of sizeable cardiac repair patches. We developed a novel bioreactor system for semi-automatic compression of a collagen I hydrogel applying 16 times higher pressure than in previous studies.
- Resistance towards compression stress was investigated for multiple cardiac-related cell types. For scaffold prevascuarization, a tubular cavity was imprinted during the compaction process. Primary cardiac-derived endothelial cells (EC) were isolated from human left atrial appendages (HLAA) and characterized by FACS and immunocytology. EC were then seeded into the preformed channel with dermal fibroblasts as interstitial cell component of the fully cellularized patch.
- After eight days of constant perfusion culture within the same bioreactor, scaffold dynamic modulus and cell viability were analyzed. Endothelial proliferation and vessel maturation were examined by immunohistochemistry and transmission electron microscopy. Our design allowed for scaffold production and dynamic culture in a one-stop-shop model.
- Enhanced compression and cell-mediated matrix remodeling induced a significant increase in scaffold stiffness while ensuring excellent cell survival. For the first time, we could isolate HLAA-derived EC with proliferative potential.
- Endothelial cells within the central channel proliferated during flow culture, continuously expressing endothelial markers (CD31) and displaying basal membrane synthesis (collagen IV, ultrastructural analysis). After seven days of culture, a complete endothelial monolayer could be observed. Covering cells aligned themselves in flow direction and developed mature cell-cell-contacts.
pharmacodane
IGF-1, rat |
|||
| RC256-12 | Bio Basic | 50ug | EUR 183.19 |
IGF-1-Fc |
|||
| E13-m003-1 | EnoGene | 10μg | EUR 185 |
|
Description: N/A |
|||
IGF-1-Fc |
|||
| E13-m003-2 | EnoGene | 50μg | EUR 600 |
|
Description: N/A |
|||
Recombinant Human LR3 IGF-I/IGF-1 |
|||
| PH2031-.01 | ApexBio | 10ug | EUR 208 |
|
Description: Peptides & Proteins|Recombinant Proteins |
|||
Recombinant Human LR3 IGF-I/IGF-1 |
|||
| PH2031-.1 | ApexBio | 10X10ug | EUR 496 |
|
Description: Peptides & Proteins|Recombinant Proteins |
|||
IGF-1, Human |
|||
| HY-P7018 | MedChemExpress | 10ug | EUR 129.6 |
IGF-1, Mouse |
|||
| HY-P7070 | MedChemExpress | 100ug | EUR 542.4 |
IGF-1 (Human) |
|||
| MBS352114-1Bottle | MyBiosource | 1Bottle | EUR 350 |
IGF-1 (Human) |
|||
| MBS352114-5x1Bottle | MyBiosource | 5x1Bottle | EUR 1490 |
IGF-1 (Human) |
|||
| MBS352116-01mL | MyBiosource | 0.1mL | EUR 450 |
IGF-1 (Human) |
|||
| MBS352116-5x01mL | MyBiosource | 5x0.1mL | EUR 1950 |
Human IGF-1 |
|||
| MBS691641-01mg | MyBiosource | 0.1mg | EUR 300 |
Human IGF-1 |
|||
| MBS691641-05mg | MyBiosource | 0.5mg | EUR 450 |
Human IGF-1 |
|||
| MBS691641-5x05mg | MyBiosource | 5x0.5mg | EUR 1725 |
Mouse IGF-1 |
|||
| MBS691927-001mg | MyBiosource | 0.01mg | EUR 300 |
Mouse IGF-1 |
|||
| MBS691927-005mg | MyBiosource | 0.05mg | EUR 450 |
Mouse IGF-1 |
|||
| MBS691927-5x005mg | MyBiosource | 5x0.05mg | EUR 1725 |
IGF-1, human |
|||
| RC216-12 | Bio Basic | 1mg | EUR 451.5 |
IGF-1 Protein |
|||
| abx060289-100ug | Abbexa | 100 ug | EUR 493.2 |
IGF-1 Antibody |
|||
| E19-6096 | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
IGF-1 Antibody |
|||
| E90303 | EnoGene | 100ul | EUR 255 |
|
Description: Available in various conjugation types. |
|||
IGF-1 Antibody |
|||
| MBS8516013-01mg | MyBiosource | 0.1mg | EUR 305 |
IGF-1 Antibody |
|||
| MBS8516013-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
IGF-1 Antibody |
|||
| MBS8516013-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
IGF-1 Antibody |
|||
| MBS8516013-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
IGF-1 Antibody |
|||
| MBS8516013-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
IGF-1 Antibody |
|||
| MBS8502303-01mL | MyBiosource | 0.1mL | EUR 325 |
IGF-1 Antibody |
|||
| MBS8502303-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
IGF-1 Antibody |
|||
| MBS8502303-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
IGF-1 Antibody |
|||
| MBS8502303-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
IGF-1 Antibody |
|||
| MBS8502303-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
IGF-1 Antibody |
|||
| MBS8000193-01mg | MyBiosource | 0.1mg | EUR 520 |
IGF-1 Antibody |
|||
| MBS8000193-5x01mg | MyBiosource | 5x0.1mg | EUR 1785 |
IGF-1 Antibody |
|||
| MBS9606757-01mL | MyBiosource | 0.1mL | EUR 260 |
IGF-1 Antibody |
|||
| MBS9606757-02mL | MyBiosource | 0.2mL | EUR 305 |
IGF-1 Antibody |
|||
| MBS9606757-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
IGF-1 Antibody |
|||
| SPC-699D | Stressmarq | 0.1mg | EUR 231.7 |
|
Description: Rabbit Anti-Human IGF-1 Polyclonal |
|||
IGF-1 Antibody |
|||
| SPC-699S | Stressmarq | 0.012mg | Ask for price |
|
Description: Rabbit Anti-Human IGF-1 Polyclonal |
|||
Recombinant IGF-1 |
|||
| MBS201105-001mg | MyBiosource | 0.01mg | EUR 340 |
Recombinant IGF-1 |
|||
| MBS201105-005mg | MyBiosource | 0.05mg | EUR 765 |
Recombinant IGF-1 |
|||
| MBS201105-5x005mg | MyBiosource | 5x0.05mg | EUR 3195 |
Recombinant Mouse IGF1/IGF?I/IGF-1 Protein |
|||
| PKSM040958-50ug | Elabscience Biotech | 50ug | EUR 281 |
|
Description: Mouse |
|||
RM-1 Cell Line |
|||
| CL-0198 | Elabscience Biotech | 1×10⁶ cells/vial | EUR 420 |
|
Description: Mus musculus, Mouse |
|||
Recombinant Mouse IGF1/IGF-I/IGF-1 Protein |
|||
| MBS2553438-005mg | MyBiosource | 0.05mg | EUR 295 |
Recombinant Mouse IGF1/IGF-I/IGF-1 Protein |
|||
| MBS2553438-5x005mg | MyBiosource | 5x0.05mg | EUR 1320 |
IGF- 1 Plasmid |
|||
| PVT7112 | Lifescience Market | 2 ug | EUR 319.2 |
IGF- 1 Antibody |
|||
| ABD6096 | Lifescience Market | 100 ug | EUR 525.6 |
RM-581 |
|||
| HY-147526 | MedChemExpress | Get quote | Ask for price |
|
Description: RM-581, an aminosteroid derivative, has potent anticancer activity in different types of cancer, including high fatality pancreatic cancer[1]. RM-581 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. |
|||
RM-018 |
|||
| HY-141477 | MedChemExpress | 10 mg | EUR 8117.01 |
|
Description: RM-018 is a potent, functionally distinct tricomplex KRASG12C active-state inhibitor. RM-018 retains the ability to bind and inhibit KRASG12C/Y96D and could overcome resistance. RM-018 binds specifically to the GTP-bound, active [“RAS(ON)”] state of KRASG12C[1]. |
|||
RM 06 |
|||
| MBS5775831-5mg | MyBiosource | 5(mg | EUR 915 |
RM 06 |
|||
| MBS5775831-5x5mg | MyBiosource | 5x5(mg | EUR 3970 |
RM 49 |
|||
| MBS5775832-5mg | MyBiosource | 5(mg | EUR 915 |
RM 49 |
|||
| MBS5775832-5x5mg | MyBiosource | 5x5(mg | EUR 3970 |
RM-133 |
|||
| MBS5783842-INQUIRE | MyBiosource | INQUIRE | Ask for price |
RM-018 |
|||
| MBS5785668-10mg | MyBiosource | 10mg | EUR 2670 |
RM-018 |
|||
| MBS5785668-25mg | MyBiosource | 25(mg | EUR 4350 |
RM-018 |
|||
| MBS5785668-5mg | MyBiosource | 5(mg | EUR 1685 |
RM-018 |
|||
| T40269-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: RM-018 |
|||
RM-018 |
|||
| T40269-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: RM-018 |
|||
RM-018 |
|||
| T40269-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: RM-018 |
|||
RM-018 |
|||
| T40269-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: RM-018 |
|||
RM-018 |
|||
| T40269-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: RM-018 |
|||
RM 06 |
|||
| T26101-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: RM 06 |
|||
RM 06 |
|||
| T26101-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: RM 06 |
|||
RM 06 |
|||
| T26101-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: RM 06 |
|||
RM 06 |
|||
| T26101-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: RM 06 |
|||
RM 06 |
|||
| T26101-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: RM 06 |
|||
RM 49 |
|||
| T26102-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: RM 49 |
|||
RM 49 |
|||
| T26102-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: RM 49 |
|||
RM 49 |
|||
| T26102-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: RM 49 |
|||
RM 49 |
|||
| T26102-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: RM 49 |
|||
RM 49 |
|||
| T26102-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: RM 49 |
|||
RM-133 |
|||
| T34335-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: RM-133 |
|||
RM-133 |
|||
| T34335-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: RM-133 |
|||
RM-133 |
|||
| T34335-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: RM-133 |
|||
RM-133 |
|||
| T34335-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: RM-133 |
|||
RM-133 |
|||
| T34335-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: RM-133 |
|||
rHu IGF-1 (cGMP) |
|||
| AK9901-0000 | Akron Biotech | 1mg | Ask for price |
IGF-1 ELISA Kit |
|||
| 80572 | Crystal Chem | 96 | EUR 490 |
IGF-1 ELISA Kit |
|||
| DEIA1901 | Creative Diagnostics | 96T | EUR 588 |
|
Description: serum |
|||
Human IGF-1 LR3 |
|||
| MBS692296-02mg | MyBiosource | 0.2mg | EUR 300 |
Human IGF-1 LR3 |
|||
| MBS692296-1mg | MyBiosource | 1mg | EUR 450 |
Human IGF-1 LR3 |
|||
| MBS692296-5x1mg | MyBiosource | 5x1mg | EUR 1725 |
Human IGF-1 LR3 |
|||
| SP-89927-100 | Alpha Diagnostics | 100 ug | EUR 270 |
Human IGF-1 ELISA |
|||
| TBS3251 | Tribioscience | 1x96-well plate | EUR 450 |
|
Description: Cell culture Supernate, Plasma/Serum IGF-1 |
|||
IGF-1(M23) Antibody |
|||
| BNCP0220-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against IGF-1(M23), PerCP conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNCR0220-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against IGF-1(M23), RPE conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNCAP0220-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IGF-1(M23), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNCAP0220-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IGF-1(M23), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNCH0220-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IGF-1(M23), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNCH0220-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IGF-1(M23), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNCA0220-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against IGF-1(M23), APC conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC430220-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IGF-1(M23), CF543 conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC430220-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IGF-1(M23), CF543 conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC550220-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IGF-1(M23), CF555 conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC550220-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IGF-1(M23), CF555 conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC610220-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IGF-1(M23), CF660R conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC610220-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IGF-1(M23), CF660R conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC050220-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IGF-1(M23), CF405M conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC050220-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IGF-1(M23), CF405M conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC700220-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IGF-1(M23), CF770 conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC700220-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IGF-1(M23), CF770 conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC810220-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IGF-1(M23), CF680R conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC810220-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IGF-1(M23), CF680R conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC800220-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against IGF-1(M23), CF680 conjugate, Concentration: 0.1mg/mL |
|||
IGF-1(M23) Antibody |
|||
| BNC800220-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against IGF-1(M23), CF680 conjugate, Concentration: 0.1mg/mL |
|||
IGF-1 Antibody: HRP |
|||
| MBS8000206-01mg | MyBiosource | 0.1mg | EUR 555 |
IGF-1 Antibody: HRP |
|||
| MBS8000206-5x01mg | MyBiosource | 5x0.1mg | EUR 1970 |
IGF-1 Antibody: RPE |
|||
| MBS8000209-01mg | MyBiosource | 0.1mg | EUR 565 |
IGF-1 Antibody: RPE |
|||
| MBS8000209-5x01mg | MyBiosource | 5x0.1mg | EUR 2010 |
IGF-1 Antibody: APC |
|||
| SPC-699D-APC | Stressmarq | 0.1mg | EUR 268.1 |
|
Description: Rabbit Anti-Human IGF-1 Polyclonal |
|||
IGF-1 Antibody: HRP |
|||
| SPC-699D-HRP | Stressmarq | 0.1mg | EUR 259.7 |
|
Description: Rabbit Anti-Human IGF-1 Polyclonal |
|||
IGF-1 Antibody: RPE |
|||
| SPC-699D-RPE | Stressmarq | 0.1mg | EUR 266.7 |
|
Description: Rabbit Anti-Human IGF-1 Polyclonal |
|||
Human IGF-1 Protein |
|||
| E2PD201113 | EnoGene | 20ug | EUR 595 |
IGF-1 Antibody: FITC |
|||
| MBS8000205-01mg | MyBiosource | 0.1mg | EUR 560 |
IGF-1 Antibody: FITC |
|||
| MBS8000205-5x01mg | MyBiosource | 5x0.1mg | EUR 1990 |
IGF-1 Antibody: FITC |
|||
| SPC-699D-FITC | Stressmarq | 0.1mg | EUR 262.5 |
|
Description: Rabbit Anti-Human IGF-1 Polyclonal |
|||
Mouse IGF-1 protein |
|||
| PRP1146-100ug | Abbkine | 100 μg | EUR 199 |
Mouse IGF-1 protein |
|||
| PRP1146-1mg | Abbkine | 1 mg | Ask for price |
Mouse IGF-1 protein |
|||
| PRP1146-20ug | Abbkine | 20 μg | EUR 89 |
Mouse IGF-1 protein |
|||
| PRP1146-500ug | Abbkine | 500 μg | EUR 669 |
Mouse IGF-1 Antibody |
|||
| 33079-05111 | AssayPro | 150 ug | EUR 215 |
IGF-1 Antibody: PerCP |
|||
| MBS8000208-01mg | MyBiosource | 0.1mg | EUR 570 |
IGF-1 Antibody: PerCP |
|||
| MBS8000208-5x01mg | MyBiosource | 5x0.1mg | EUR 2020 |
IGF-1 Antibody: PerCP |
|||
| SPC-699D-PCP | Stressmarq | 0.1mg | EUR 268.1 |
|
Description: Rabbit Anti-Human IGF-1 Polyclonal |
|||
IGF-1 Antibody: Biotin |
|||
| MBS8000204-01mg | MyBiosource | 0.1mg | EUR 565 |
IGF-1 Antibody: Biotin |
|||
| MBS8000204-5x01mg | MyBiosource | 5x0.1mg | EUR 2005 |
Recombinant Rat IGF-1 |
|||
| P1203-.01 | ApexBio | 10ug | EUR 108.8 |
|
Description: Peptides & Proteins|Recombinant Proteins |
|||
Recombinant Rat IGF-1 |
|||
| P1203-.1 | ApexBio | 100ug | EUR 504.8 |
|
Description: Peptides & Proteins|Recombinant Proteins |
|||
Recombinant Rat IGF-1 |
|||
| P1203-.5 | ApexBio | 500ug | EUR 1132 |
|
Description: Peptides & Proteins|Recombinant Proteins |
|||
IGF-1 Antibody: Biotin |
|||
| SPC-699D-BI | Stressmarq | 0.1mg | EUR 266 |
|
Description: Rabbit Anti-Human IGF-1 Polyclonal |
|||
Recombinant Rat IGF-1 |
|||
| REGFP-0901 | Cyagen | 10ug | Ask for price |
Plant cell cultures as food-aspects of sustainability and safety
Sustainability and safety aspects of plant cell cultures as food are presented. Applicability of dairy side streams as carbon source and use of natural growth enhancers in cultivation are shown. Biotechnologically produced cellular products are currently emerging to replace and add into the portfolio of agriculturally derived commodities.
Plant cell cultures used for food could supplement current food production. However, still many aspects need to be resolved before this new food concept can enter the market. Issues related to sustainability and safety for human consumption are relevant for both consumers and regulators. In this study, two plant cell cultures, deriving from arctic bramble (Rubus arcticus) and birch (Betula pendula), were cultivated using lactose-rich dairy side streams as alternative carbon sources to replace sucrose.
Biomasses were comparable to those of original plant cell culture media when up to 83% and 75% of the original sucrose was replaced by these side streams for arctic bramble and birch cell cultures, respectively. Furthermore, nutritional composition or sensory properties were not compromised. Synthetic plant growth regulators were replaced by natural components, such as coconut water and IAA for several subculture cycles.
Finally, it was shown that only trace amounts of free growth regulators are present in the cells at the harvesting point and assessment by freshwater crustaceans assay indicated that toxicity of the cells was not exceeding that of traditionally consumed bilberry fruit.
Stability of live attenuated classical swine fever cellculture vaccine virus in liquid form for developing an oral vaccine
Classical swine fever (CSF) is an important viral disease of pigs and controlled by vaccination. Unorganised backyard and wild pigs are difficult to vaccinate by needle vaccination. Here we formulated liquid vaccines using an Indian CSF cell culture vaccine virus and four stabilisers and evaluated their stability at 4 °C, 25 °C and 37 °C up to 24 h for use as oral vaccine.
The stabilisers were Lactalbumin hydrolysate-Trehalose, Lactalbumin hydrolysate-Trehalose-Gelatin, Lactalbumin hydrolysate-Lactose-Sucrose and Lactalbumin hydrolysate-Sucrose. The liquid vaccines, with or without stabilisers, were stable at 4 °C up to 24 h, whereas, a drop of one log10 titre was observed at 25 °C during the same period. At 37 °C, the virus titre diminished by only one log10 with the Lactalbumin hydrolysate-Trehalose (LT) stabiliser up to 24 h compared to two log10 losses in virus titre with other stabilisers and virus control.
We therefore conclude that for developing a CSF oral vaccine, the vaccine virus in liquid form can be used directly during the winter, whereas for developing the oral vaccine for summer, the LT stabiliser would provide maximum stability to the virus to withstand the warm temperature while maintaining adequate therapeutic titre for inducing a protective immune response.
rHu VEGF-121 |
|||
| AK8331-0002 | Akron Biotech | 2µg | Ask for price |
rHu VEGF-121 |
|||
| AK8331-0010 | Akron Biotech | 10µg | Ask for price |
rHu VEGF-121 |
|||
| AK8331-0100 | Akron Biotech | 100µg | Ask for price |
rHu VEGF-121 |
|||
| AK8331-1000 | Akron Biotech | 1mg | Ask for price |
rHu VEGF (cGMP) |
|||
| AK9063-0000 | Akron Biotech | 1mg | Ask for price |
EG VEGF |
|||
| cyt-338 | ProSpec Tany | 5µg | EUR 60 |
|
Description: Recombinant Human Endocrine Gland Vascular Endothelial Growth Factor |
|||
EG VEGF protein |
|||
| 30R-AE013 | Fitzgerald | 20 ug | EUR 358 |
|
Description: Purified recombinant Human EG VEGF protein |
|||
EG VEGF protein |
|||
| MBS539573-002mg | MyBiosource | 0.02mg | EUR 1450 |
EG VEGF protein |
|||
| MBS539573-5x002mg | MyBiosource | 5x0.02mg | EUR 6380 |
EG VEGF antibody |
|||
| 20R-1607 | Fitzgerald | 100 ug | EUR 807.6 |
|
Description: Rabbit polyclonal EG VEGF antibody |
|||
EG VEGF antibody |
|||
| 70R-EG002 | Fitzgerald | 50 ug | EUR 312 |
|
Description: Affinity purified Goat polyclonal EG VEGF antibody |
|||
EG VEGF antibody |
|||
| MBS535877-005mg | MyBiosource | 0.05mg | EUR 465 |
EG VEGF antibody |
|||
| MBS535877-5x005mg | MyBiosource | 5x0.05mg | EUR 1945 |
EG VEGF Rabbit mAb |
|||
| E2R389402 | EnoGene | 100ul | EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
Recombinant Mouse EG VEGF |
|||
| MBS7610489-005mg | MyBiosource | 0.05mg | EUR 345 |
Recombinant Mouse EG VEGF |
|||
| MBS7610489-02mg | MyBiosource | 0.2mg | EUR 635 |
Recombinant Mouse EG VEGF |
|||
| MBS7610489-1mg | MyBiosource | 1mg | EUR 1800 |
Recombinant Mouse EG VEGF |
|||
| MBS7610489-5x1mg | MyBiosource | 5x1mg | EUR 6955 |
OPPA00601-5UG - EG VEGF Protein |
|||
| OPPA00601-5UG | Aviva Systems Biology | 5ug | EUR 70 |
Recombinant Human VEGF165 (rHu VEGF165) |
|||
| 70505 | SAB | 10ul | EUR 235 |
|
Description: Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human umbilical vein endothelial cells(HUVEC) is between 1.0-8.0 ng/ml. |
|||
Recombinant Human VEGF165 (rHu VEGF165) |
|||
| MBS9419932-001mL | MyBiosource | 0.01mL | EUR 280 |
Recombinant Human VEGF165 (rHu VEGF165) |
|||
| MBS9419932-5x001mL | MyBiosource | 5x0.01mL | EUR 1120 |
EG-VEGF |
|||
| PR29003 | Neuromics | 5 ug | EUR 277.2 |
Recombinant Mouse EG VEGF Protein, Untagged, E.coli-1mg |
|||
| QP11757-1mg | EnQuireBio | 1mg | EUR 3308.4 |
Recombinant Mouse EG VEGF Protein, Untagged, E.coli-5ug |
|||
| QP11757-5ug | EnQuireBio | 5ug | EUR 186 |
Recombinant Mouse EG VEGF Protein, Untagged, E.coli-20ug |
|||
| QP11757-20ug | EnQuireBio | 20ug | EUR 241.2 |
EG-VEGF Antibody |
|||
| 3489-100 | Biovision | each | EUR 405.6 |
EG-VEGF Antibody |
|||
| 3489R-100 | Biovision | each | EUR 379.2 |
EG-VEGF Antibody |
|||
| 3489R-30T | Biovision | each | EUR 175.2 |
EG-VEGF Antibody |
|||
| E38PA3084 | EnoGene | 100ug/100ul | EUR 225 |
Human EG-VEGF |
|||
| MBS692179-0005mg | MyBiosource | 0.005mg | EUR 300 |
Human EG-VEGF |
|||
| MBS692179-002mg | MyBiosource | 0.02mg | EUR 450 |
Human EG-VEGF |
|||
| MBS692179-5x002mg | MyBiosource | 5x0.02mg | EUR 1725 |
Mouse EG-VEGF |
|||
| MBS691769-0005mg | MyBiosource | 0.005mg | EUR 300 |
Mouse EG-VEGF |
|||
| MBS691769-002mg | MyBiosource | 0.02mg | EUR 450 |
Mouse EG-VEGF |
|||
| MBS691769-5x002mg | MyBiosource | 5x0.02mg | EUR 1725 |
Rat Endocrine gland vascular endothelial growth factor, EG- VEGF |
|||
| ELA-E0024r | Lifescience Market | 96 Tests | EUR 1063.2 |
EG-VEGF Recombinant Protein |
|||
| 40-629 | ProSci | 5 ug | EUR 311.1 |
|
Description: EG-VEGF is a secreted angiogenetic mitogen growth factor expressed in the steroidogenic glands, ovary, testis, adrenal gland, and placenta. EG-VEGF induces proliferation, migration, and fenestration (formation of membrane discontinuities) in capillary endothelial cells derived from endocrine glands. The human EG-VEGF gene codes for a 105 amino acid polypeptide containing an N-terminal signal sequence of 19 amino acids. Recombinant Human EG-VEGF is a 9.6 kDa protein consisting of 86 amino acid residues, including ten cysteine residues that potentially form five pairs of intra-molecular disulfide bonds. |
|||
EG-VEGF Recombinant Protein |
|||
| 40-702 | ProSci | 5 ug | EUR 311.1 |
|
Description: EG-VEGF is a secreted angiogenetic mitogen growth factor expressed in the steroidogenic glands, ovary, testis, adrenal gland, and placenta. EG-VEGF induces proliferation, migration, and fenestration (formation of membrane discontinuities) in capillary endothelial cells derived from endocrine glands. The murine EG-VEGF gene codes for a 105 amino acid polypeptide containing an N-terminal signal sequence of 19 amino acids. Recombinant Murine EG-VEGF is a 9.6 kDa protein consisting of 86 amino acid residues, including ten cysteine residues that potentially form five pairs of intra-molecular disulfide bonds. |
|||
EG-VEGF, human recombinant |
|||
| 4571-10 | Biovision | each | EUR 183.6 |
EG-VEGF, human recombinant |
|||
| 4571-1000 | Biovision | each | EUR 3583.2 |
EG-VEGF, human recombinant |
|||
| 4571-50 | Biovision | each | EUR 483.6 |
Polyclonal EG-VEGF Antibody |
|||
| APR00114G | Leading Biology | 0.1mg | EUR 580.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human EG-VEGF . This antibody is tested and proven to work in the following applications: |
|||
Polyclonal EG-VEGF Antibody |
|||
| APG00002G | Leading Biology | 0.1ml | EUR 580.8 |
|
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human EG-VEGF . This antibody is tested and proven to work in the following applications: |
|||
EG-VEGF Blocking Peptide |
|||
| 20-abx064278 | Abbexa |
|
|
Anti-EG-VEGF Antibody |
|||
| HA500078 | HUABIO | 100ul | EUR 189 |
|
Description: The protein encoded by this gene induces proliferation, migration, and fenestration (the formation of membrane discontinuities) in capillary endothelial cells derived from endocrine glands. It has little or no effect on a variety of other endothelial and non-endothelial cell types. Its expression is restricted to the steroidogenic glands (ovary, testis, adrenal, and placenta), is induced by hypoxia, and often complementary to the expression of vascular endothelial growth factor (VEGF), suggesting that these molecules function in a coordinated manner. |
|||
Recombinant Human EG-VEGF |
|||
| HEGFP-0503 | Cyagen | 5ug | Ask for price |
EG-VEGF ELISA Kit |
|||
| MBS495251-5x96Tests | MyBiosource | 5x96Tests | EUR 3180 |
EG-VEGF ELISA Kit |
|||
| MBS495251-96Tests | MyBiosource | 96Tests | EUR 695 |
Recombinant Human EG-VEGF |
|||
| MBS7610109-005mg | MyBiosource | 0.05mg | EUR 345 |
Recombinant Human EG-VEGF |
|||
| MBS7610109-02mg | MyBiosource | 0.2mg | EUR 635 |
Recombinant Human EG-VEGF |
|||
| MBS7610109-1mg | MyBiosource | 1mg | EUR 1800 |
Recombinant Human EG-VEGF |
|||
| MBS7610109-5x1mg | MyBiosource | 5x1mg | EUR 6955 |
Recombinant Murine EG-VEGF |
|||
| MEGFP-0502 | Cyagen | 5ug | Ask for price |
EG-VEGF Blocking Peptide |
|||
| MBS824014-1mg | MyBiosource | 1mg | EUR 190 |
EG-VEGF Blocking Peptide |
|||
| MBS824014-5mg | MyBiosource | 5mg | EUR 345 |
EG-VEGF Blocking Peptide |
|||
| MBS824014-5x5mg | MyBiosource | 5x5mg | EUR 1465 |
Anti-EG-VEGF Antibody |
|||
| MBS821147-003mL | MyBiosource | 0.03mL | EUR 185 |
Anti-EG-VEGF Antibody |
|||
| MBS821147-01mL | MyBiosource | 0.1mL | EUR 255 |
Anti-EG-VEGF Antibody |
|||
| MBS821147-02mL | MyBiosource | 0.2mL | EUR 335 |
Anti-EG-VEGF Antibody |
|||
| MBS821147-5x02mL | MyBiosource | 5x0.2mL | EUR 1420 |
VEGF-A(VEGF/1063) Antibody |
|||
| BNC051063-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC051063-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC431063-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC431063-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC701063-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC701063-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNCP1063-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNCR1063-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC811063-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC811063-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC551063-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC551063-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNCH1063-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNCH1063-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNCAP1063-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNCAP1063-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNCA1063-250 | Biotium | 250uL | EUR 459.6 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC801063-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC801063-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC611063-100 | Biotium | 100uL | EUR 238.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063) Antibody |
|||
| BNC611063-500 | Biotium | 500uL | EUR 652.8 |
|
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL |
|||
VEGF-A(VEGF/1063), 0.2mg/mL |
|||
| BNUB1063-100 | Biotium | 100uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
VEGF-A(VEGF/1063), 0.2mg/mL |
|||
| BNUB1063-500 | Biotium | 500uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
VEGF-A(VEGF/1063), 1mg/mL |
|||
| BNUM1063-50 | Biotium | 50uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
VEGF/ Rat VEGF ELISA Kit |
|||
| ELA-E0143r | Lifescience Market | 96 Tests | EUR 1063.2 |
Human EG-VEGF Recombinant Protein |
|||
| 100-150 | ReliaTech | 20 µg | EUR 196.35 |
|
Description: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) induces proliferation, migration, and fenestration in capillary endothelial cells derived from endocrine glands. Its expression is induced by hypoxia and is restricted to the steroidogenic glands (ovary, testis, adrenal, and placenta). Its expression is often complementary to the expression of VEGF (MIM 192240), suggesting that these molecules function in a coordinated manner. EG-VEGF potently contracts gastrointestinal (gi) smooth muscle. Induces proliferation, migration and fenestration (the formation of membrane discontinuities) in capillary endothelial cells derived from endocrine glands. Has little or no effect on a variety of other endothelial and non-endothelial cell types. |
|||
Human EG-VEGF Recombinant Protein |
|||
| 100-150S | ReliaTech | 5 µg | EUR 92.4 |
|
Description: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) induces proliferation, migration, and fenestration in capillary endothelial cells derived from endocrine glands. Its expression is induced by hypoxia and is restricted to the steroidogenic glands (ovary, testis, adrenal, and placenta). Its expression is often complementary to the expression of VEGF (MIM 192240), suggesting that these molecules function in a coordinated manner. EG-VEGF potently contracts gastrointestinal (gi) smooth muscle. Induces proliferation, migration and fenestration (the formation of membrane discontinuities) in capillary endothelial cells derived from endocrine glands. Has little or no effect on a variety of other endothelial and non-endothelial cell types. |
|||
Anti-Human EG-VEGF Antibody |
|||
| 101-M158 | ReliaTech | 100 µg | EUR 399 |
|
Description: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF), also called prokineticin 1 (PK1), is a member of the prokineticin family of secreted proteins that share a common structural motif containing ten conserved cysteine residues that form five pairs of disulfide bonds. Members of this family include the mammalian EG-VEGF/ PK1 and PK2, as well as the venom protein A (VPRA) from the venom of black mamba snake and the frog Bombina variegata, Bv8. Human EG-VEGF precursor is a 105 amino acid (aa) residue protein with a 19 aa signal peptide that is cleaved to yield a 86 aa mature protein. EG-VEGF is expressed in multiple tissues including the gastrointestinal (GI) tract and steroidogenic glands (testis, ovary, placenta and adrenal glands). EG-VEGF has been shown to potently stimulate the contraction of GI smooth muscle. In addition, EG-VEGF is a tissue-specific angiogenic factor that exhibits biological activities similar to that of VEGF on select cells. It induces the proliferation, migration, and fenestration in cultured endocrine gland-derived capillary endothelial cells. EG-VEGF binds to and activates two closely related G proteincoupled receptors, EG-VEGF/ PK1R1 and EG-VEGF/ PK2R2. Activation of the receptors leads to stimulation of phosphoinositide turnover and activation of p44/p42 MAP kinase signaling pathways. |
|||
Anti-Human EG-VEGF Antibody |
|||
| 101-M633 | ReliaTech | 100 µg | EUR 399 |
|
Description: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF), also called prokineticin 1 (PK1), is a member of the prokineticin family of secreted proteins that share a common structural motif containing ten conserved cysteine residues that form five pairs of disulfide bonds. Members of this family include the mammalian EG-VEGF/ PK1 and PK2, as well as the venom protein A (VPRA) from the venom of black mamba snake and the frog Bombina variegata, Bv8. Human EG-VEGF precursor is a 105 amino acid (aa) residue protein with a 19 aa signal peptide that is cleaved to yield a 86 aa mature protein. EG-VEGF is expressed in multiple tissues including the gastrointestinal (GI) tract and steroidogenic glands (testis, ovary, placenta and adrenal glands). EG-VEGF has been shown to potently stimulate the contraction of GI smooth muscle. In addition, EG-VEGF is a tissue-specific angiogenic factor that exhibits biological activities similar to that of VEGF on select cells. It induces the proliferation, migration, and fenestration in cultured endocrine gland-derived capillary endothelial cells. EG-VEGF binds to and activates two closely related G proteincoupled receptors, EG-VEGF/ PK1R1 and EG-VEGF/ PK2R2. Activation of the receptors leads to stimulation of phosphoinositide turnover and activation of p44/p42 MAP kinase signaling pathways. |
|||
Anti-Human EG-VEGF Antibody |
|||
| 102-P113G | ReliaTech | 100 µg | EUR 245.7 |
|
Description: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF), also called prokineticin 1 (PK1), is a member of the prokineticin family of secreted proteins that share a common structural motif containing ten conserved cysteine residues that form five pairs of disulfide bonds. Members of this family include the mammalian EG-VEGF/ PK1 and PK2, as well as the venom protein A (VPRA) from the venom of black mamba snake and the frog Bombina variegata, Bv8. Human EG-VEGF precursor is a 105 amino acid (aa) residue protein with a 19 aa signal peptide that is cleaved to yield a 86 aa mature protein. EG-VEGF is expressed in multiple tissues including the gastrointestinal (GI) tract and steroidogenic glands (testis, ovary, placenta and adrenal glands). EG-VEGF has been shown to potently stimulate the contraction of GI smooth muscle. In addition, EG-VEGF is a tissue-specific angiogenic factor that exhibits biological activities similar to that of VEGF on select cells. It induces the proliferation, migration, and fenestration in cultured endocrine gland-derived capillary endothelial cells. EG-VEGF binds to and activates two closely related G proteincoupled receptors, EG-VEGF/ PK1R1 and EG-VEGF/ PK2R2. Activation of the receptors leads to stimulation of phosphoinositide turnover and activation of p44/p42 MAP kinase signaling pathways. |
|||
Prokineticin 1 (EG-VEGF) Antibody |
|||
| 20-abx007755 | Abbexa |
|
|
Rabbit anti-EG-VEGF Antibody |
|||
| DL92084A-100ul | DL Develop | 100 ul | EUR 299 |
|
Description: Prokineticin-1; Endocrine-gland-derived vascular endothelial growth factor; EG-VEGF; Mambakine |
|||
Rabbit anti-EG-VEGF Antibody |
|||
| DL92084A-50ul | DL Develop | 50 ul | EUR 209.3 |
|
Description: Prokineticin-1; Endocrine-gland-derived vascular endothelial growth factor; EG-VEGF; Mambakine |
|||
Human EG-VEGF ELISA Kit |
|||
| GWB-SKR013 | GenWay Biotech | 96 Tests | Ask for price |
Human EG-VEGF ELISA Kit |
|||
| GWB-ZZD183 | GenWay Biotech | 1x96 well plate | Ask for price |
Human EG-VEGF ELISA Kit |
|||
| EK5247 | SAB | 96 tests | EUR 599 |
Mouse EG-VEGF ELISA Kit |
|||
| EME0137 | Abclonal | 96Tests | EUR 625.2 |
Monkey EG-VEGF ELISA Kit |
|||
| EMKE0137 | Abclonal | 96Tests | EUR 625.2 |
Sheep EG-VEGF ELISA Kit |
|||
| ESE0137 | Abclonal | 96Tests | EUR 625.2 |
Porcine EG-VEGF ELISA Kit |
|||
| EPE0137 | Abclonal | 96Tests | EUR 625.2 |
Rat EG-VEGF ELISA Kit |
|||
| ERE0137 | Abclonal | 96Tests | EUR 625.2 |
Rabbit EG-VEGF ELISA Kit |
|||
| ERTE0137 | Abclonal | 96Tests | EUR 625.2 |
Chicken EG-VEGF ELISA Kit |
|||
| ECKE0137 | Abclonal | 96Tests | EUR 625.2 |
EG-VEGF ELISA KIT|Human |
|||
| EF000094 | Lifescience Market | 96 Tests | EUR 826.8 |
Bovine EG-VEGF ELISA Kit |
|||
| EBE0137 | Abclonal | 96Tests | EUR 625.2 |
Canine EG-VEGF ELISA Kit |
|||
| ECE0137 | Abclonal | 96Tests | EUR 625.2 |
Anserini EG-VEGF ELISA Kit |
|||
| EAE0137 | Abclonal | 96Tests | EUR 625.2 |
Goat EG-VEGF ELISA Kit |
|||
| EGTE0137 | Abclonal | 96Tests | EUR 625.2 |
EG-VEGF (Human) ELISA Kit |
|||
| EKA51829-5x96T | Biomatik Corporation | 5x96T | Ask for price |
EG-VEGF (Human) ELISA Kit |
|||
| EKA51829-96T | Biomatik Corporation | 96T | EUR 446.9 |
Human EG-VEGF ELISA Kit |
|||
| EHE0137 | Abclonal | 96Tests | EUR 625.2 |
Mouse EG-VEGF Recombinant Protein |
|||
| M10-236 | ReliaTech | 20 µg | EUR 196.35 |
|
Description: EG-VEGF is a secreted angiogenetic mitogen growth factor expressed in the steroidogenic glands, ovary, testis, adrenal and placenta. EG-VEGF induces proliferation and migration fenestration (formation of membrane discontinuities) in capillary endothelial cells derived from endocrine glands. The murine EG-VEGF gene codes for a 105 amino acid polypeptide containing an N-terminal signal sequence of 19 amino acids. Recombinant murine EG-VEGF is a 9.6 kDa protein consisting of 86 amino acid residues and ten cysteine residues that potentially form five pairs of intra-molecular disulfide bonds. |
|||
Mouse EG-VEGF Recombinant Protein |
|||
| M10-236S | ReliaTech | 5 µg | EUR 92.4 |
|
Description: EG-VEGF is a secreted angiogenetic mitogen growth factor expressed in the steroidogenic glands, ovary, testis, adrenal and placenta. EG-VEGF induces proliferation and migration fenestration (formation of membrane discontinuities) in capillary endothelial cells derived from endocrine glands. The murine EG-VEGF gene codes for a 105 amino acid polypeptide containing an N-terminal signal sequence of 19 amino acids. Recombinant murine EG-VEGF is a 9.6 kDa protein consisting of 86 amino acid residues and ten cysteine residues that potentially form five pairs of intra-molecular disulfide bonds. |
|||
Human EG-VEGF GENLISA ELISA |
|||
| KB1036 | Krishgen | 1 x 96 wells | EUR 198 |
Human EG-VEGF ELISA kit |
|||
| LF-EK50695 | Abfrontier | 1×96T | EUR 777.6 |
EG-VEGF Human ELISA Kit |
|||
| MBS355293-5x96Tests | MyBiosource | 5x96Tests | EUR 2280 |
EG-VEGF Human ELISA Kit |
|||
| MBS355293-96Tests | MyBiosource | 96Tests | EUR 505 |
Recombinant Human EG-VEGF (PROK1) |
|||
| MBS4159644-002mg | MyBiosource | 0.02mg | EUR 385 |
Recombinant Human EG-VEGF (PROK1) |
|||
| MBS4159644-1mg | MyBiosource | 1(mg) | EUR 4600 |
Recombinant Human EG-VEGF (PROK1) |
|||
| MBS4159644-5x1mg | MyBiosource | 5x1mg | EUR 20445 |
Human EG-VEGF ELISA Kit |
|||
| MBS824659-5x96Tests | MyBiosource | 5x96Tests | EUR 2880 |
Human EG-VEGF ELISA Kit |
|||
| MBS824659-96Tests | MyBiosource | 96Tests | EUR 645 |
OPSD00006-5UG - Recombinant EG-VEGF |
|||
| OPSD00006-5UG | Aviva Systems Biology | 5ug | EUR 108 |
Rabbit anti-EG-VEGF Antibody |
|||
| YLD2727-100ul | Shanghai YL Biotech | 100 ul | EUR 320 |
|
Description: Rabbit polyclonal antibody to EG-VEGF |
|||
Rabbit anti-EG-VEGF Antibody |
|||
| YLD2727-50ul | Shanghai YL Biotech | 50 ul | EUR 200 |
|
Description: Rabbit polyclonal antibody to EG-VEGF |
|||
Recombinant Human EG-VEGF (PROK1) |
|||
| Z100145 | ABM | 20 µg | EUR 235 |
|
Description: This factor is identical to prokineticin-1 and is a member of the AVIT protein family. Expression of human EG-VEGF messenger RNA is restricted to the steroidogenic glands, ovary, testis, adrenal and placenta and is often complementary to the expression of VEGF. EG-VEGF has been identified as a mitogen specific for the endothelium of steroidogenic glands. EG-VEGF resembles VEGF in that it causes extensive angiogenesis and cyst formation when delivered in the ovary. EG-VEGF differs from VEGF in that it does not promote angiogenesis in the cornea or skeletal muscle. Two receptors have been characterized and are expressed in gastrointestinal organs, endocrine glands and other tissues. The G-protein-coupled receptors ZAQ and I5E both function as the EG-VEGF receptor. |
|||
Recombinant Human EG-VEGF (PROK1) |
|||
| Z100149 | ABM | 1.0 mg | EUR 3900 |
|
Description: This factor is identical to prokineticin-1 and is a member of the AVIT protein family. Expression of human EG-VEGF messenger RNA is restricted to the steroidogenic glands, ovary, testis, adrenal and placenta and is often complementary to the expression of VEGF. EG-VEGF has been identified as a mitogen specific for the endothelium of steroidogenic glands. EG-VEGF resembles VEGF in that it causes extensive angiogenesis and cyst formation when delivered in the ovary. EG-VEGF differs from VEGF in that it does not promote angiogenesis in the cornea or skeletal muscle. Two receptors have been characterized and are expressed in gastrointestinal organs, endocrine glands and other tissues. The G-protein-coupled receptors ZAQ and I5E both function as the EG-VEGF receptor. |
|||
rHu MIF |
|||
| AK8255-0005 | Akron Biotech | 5µg | Ask for price |
rHu MIF |
|||
| AK8255-0025 | Akron Biotech | 25µg | Ask for price |
rHu MIF |
|||
| AK8255-0100 | Akron Biotech | 100µg | Ask for price |
rHu MIF |
|||
| AK8255-1000 | Akron Biotech | 1mg | Ask for price |
rHu EGF |
|||
| AK8327-0100 | Akron Biotech | 100µg | Ask for price |
rHu EGF |
|||
| AK8327-0500 | Akron Biotech | 500µg | Ask for price |
rHu EGF |
|||
| AK8327-1000 | Akron Biotech | 1mg | Ask for price |
rHu OSM |
|||
| AK8531-0002 | Akron Biotech | 2µg | Ask for price |
rHu OSM |
|||
| AK8531-0010 | Akron Biotech | 10µg | Ask for price |
rHu OSM |
|||
| AK8531-0100 | Akron Biotech | 100µg | Ask for price |
rHu OSM |
|||
| AK8531-1000 | Akron Biotech | 1mg | Ask for price |
rHu SHH |
|||
| AK9088-0005 | Akron Biotech | 5µg | Ask for price |
rHu SHH |
|||
| AK9088-0025 | Akron Biotech | 25µg | Ask for price |
rHu SHH |
|||
| AK9088-0100 | Akron Biotech | 100µg | Ask for price |
rHu SHH |
|||
| AK9088-1000 | Akron Biotech | 1mg | Ask for price |
rHu TPO |
|||
| AK9089-0002 | Akron Biotech | 5µg | Ask for price |
rHu TPO |
|||
| AK9089-0010 | Akron Biotech | 20µg | Ask for price |
rHu TPO |
|||
| AK9089-0100 | Akron Biotech | 100µg | Ask for price |
rHu TPO |
|||
| AK9089-1000 | Akron Biotech | 1mg | Ask for price |
rHu PTN |
|||
| AK9912-0005 | Akron Biotech | 5µg | Ask for price |
rHu PTN |
|||
| AK9912-0020 | Akron Biotech | 20µg | Ask for price |
rHu PTN |
|||
| AK9912-0100 | Akron Biotech | 100µg | Ask for price |
rHu PTN |
|||
| AK9912-1000 | Akron Biotech | 1mg | Ask for price |
rHu LIF |
|||
| AK9977-0005 | Akron Biotech | 5µg | Ask for price |
rHu LIF |
|||
| AK9977-0025 | Akron Biotech | 25µg | Ask for price |
rHu LIF |
|||
| AK9977-0100 | Akron Biotech | 100µg | Ask for price |
rHu LIF |
|||
| AK9977-1000 | Akron Biotech | 1mg | Ask for price |
rHu MIG |
|||
| AK9979-0005 | Akron Biotech | 5µg | Ask for price |
rHu MIG |
|||
| AK9979-0020 | Akron Biotech | 20µg | Ask for price |
rHu MIG |
|||
| AK9979-0100 | Akron Biotech | 100µg | Ask for price |
rHu MIG |
|||
| AK9979-1000 | Akron Biotech | 1mg | Ask for price |
rHu aFGF |
|||
| AK8230-0010 | Akron Biotech | 10µg | Ask for price |
rHu aFGF |
|||
| AK8230-0050 | Akron Biotech | 50µg | Ask for price |
rHu aFGF |
|||
| AK8230-0100 | Akron Biotech | 100µg | Ask for price |
rHu aFGF |
|||
| AK8230-1000 | Akron Biotech | 1mg | Ask for price |
rHu MCSF |
|||
| AK8238-0002 | Akron Biotech | 2µg | Ask for price |
rHu MCSF |
|||
| AK8238-0010 | Akron Biotech | 10µg | Ask for price |
rHu MCSF |
|||
| AK8238-0100 | Akron Biotech | 100µg | Ask for price |
rHu MCSF |
|||
| AK8238-1000 | Akron Biotech | 1mg | Ask for price |
rHu CTGF |
|||
| AK8240-0005 | Akron Biotech | 5µg | Ask for price |
rHu CTGF |
|||
| AK8240-0020 | Akron Biotech | 20µg | Ask for price |